37.24
전일 마감가:
$38.02
열려 있는:
$37.82
하루 거래량:
522.50K
Relative Volume:
1.33
시가총액:
$1.87B
수익:
$345.60M
순이익/손실:
$-79.01M
주가수익비율:
-23.21
EPS:
-1.6045
순현금흐름:
$-18.62M
1주 성능:
+1.75%
1개월 성능:
+32.72%
6개월 성능:
+18.15%
1년 성능:
-12.77%
이뮤노코어 홀딩스 Stock (IMCR) Company Profile
명칭
Immunocore Holdings Plc Adr
전화
01235 5430281
주소
90 PARK DRIVE, OXFORDSHIRE
IMCR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IMCR
Immunocore Holdings Plc Adr
|
37.24 | 1.76B | 345.60M | -79.01M | -18.62M | -1.6045 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
이뮤노코어 홀딩스 Stock (IMCR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-27 | 개시 | Deutsche Bank | Buy |
2024-12-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2024-11-11 | 다운그레이드 | Mizuho | Outperform → Neutral |
2024-10-24 | 개시 | UBS | Sell |
2024-10-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-04-29 | 개시 | Leerink Partners | Outperform |
2023-11-20 | 재개 | JP Morgan | Overweight |
2023-11-02 | 개시 | Cantor Fitzgerald | Overweight |
2023-10-31 | 개시 | Robert W. Baird | Outperform |
2023-09-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
2023-09-13 | 개시 | Needham | Buy |
2023-08-16 | 개시 | CapitalOne | Overweight |
2023-07-17 | 개시 | Canaccord Genuity | Hold |
2023-03-31 | 개시 | Mizuho | Buy |
2023-03-30 | 개시 | Guggenheim | Buy |
2023-03-24 | 개시 | Bryan Garnier | Buy |
2022-12-16 | 업그레이드 | Goldman | Neutral → Buy |
2022-11-30 | 개시 | Barclays | Overweight |
2022-09-09 | 개시 | Morgan Stanley | Overweight |
2022-09-08 | 개시 | Ladenburg Thalmann | Buy |
2022-08-08 | 개시 | Cowen | Outperform |
2022-08-02 | 개시 | BTIG Research | Buy |
2022-02-08 | 개시 | H.C. Wainwright | Buy |
2021-10-20 | 개시 | Oppenheimer | Outperform |
2021-03-02 | 개시 | Goldman | Neutral |
2021-03-02 | 개시 | JP Morgan | Overweight |
2021-03-02 | 개시 | Jefferies | Buy |
모두보기
이뮤노코어 홀딩스 주식(IMCR)의 최신 뉴스
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet - sharewise
Deutsche Bank sets $65 target on Immunocore stock, rates Buy By Investing.com - Investing.com India
Deutsche Bank sets $65 target on Immunocore stock, rates Buy - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock faces challenges amid growth - Investing.com
Is it a Good Idea to Invest in Immunocore Stock Right Now? - MSN
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
Balance Sheet Dive: Hippo Holdings Inc (HIPO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX
New Strong Buy Stocks for May 8th - The Globe and Mail
Immunocore stock rises as Q1 results top estimates By Investing.com - Investing.com South Africa
Immunocore stock rises as Q1 results top estimates - Investing.com
Immunocore Holdings earnings beat by $0.49, revenue topped estimates - Investing.com
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down - Barchart.com
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y - The Globe and Mail
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates - Barchart.com
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y - Barchart.com
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet - Yahoo Finance
Mizuho cuts Immunocore stock price target to $33 from $38 - Investing.com
Immunocore stock hits 52-week low at $27.19 amid market challenges By Investing.com - Investing.com South Africa
Immunocore stock hits 52-week low at $27.19 amid market challenges - Investing.com
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $100 target on Immunocore stock - Investing.com
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
PBYI Stock Rises as Q4 Earnings & Sales Outpace EstimatesFebruary 28, 2025 - Zacks Investment Research
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings earnings missed by $0.23, revenue fell short of estimates - Investing.com
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat - Yahoo Finance
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales - Yahoo Finance
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store? - MSN
A stock that deserves closer examination: Empresa Distribuidora y Comercial Norte S.A. ADR (EDN) - US Post News
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
이뮤노코어 홀딩스 (IMCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):